NCT01598792 - Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

HPV-16 +ve Oropharyngeal Carcinoma

Interventions

BIOLOGICAL

ADXS11-001

Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).

Trial Locations (4)

CF14 2TL

Velindre NHS Trust, Cardiff

L7 8XP

The Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Liverpool

L9 7AL

Aintree University NHS Foundation Trust, Liverpool

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London